These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 31088567)

  • 1. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
    Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
    J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
    Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
    Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo.
    Deng M; Yan P; Gong H; Li G; Wang J
    Mol Med; 2024 Jun; 30(1):95. PubMed ID: 38910244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
    Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
    Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LINC00982-encoded protein PRDM16-DT regulates
    Hu HF; Han L; Fu JY; He X; Tan JF; Chen QP; Han JR; He QY
    Theranostics; 2024; 14(8):3317-3338. PubMed ID: 38855188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100A6 mediated epithelial-mesenchymal transition affects chemosensitivity of colorectal cancer to oxaliplatin.
    Zhang C; Zeng M; Xu Y; Huang B; Shi P; Zhu X; Cao Y
    Gene; 2024 Jul; 914():148406. PubMed ID: 38521111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
    Lu WQ; Hu YY; Lin XP; Fan W
    Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
    Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
    J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
    Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
    Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of EIF4A2 in non-small-cell lung cancer associates with poor prognosis.
    Shaoyan X; Juanjuan Y; Yalan T; Ping H; Jianzhong L; Qinian W
    Clin Lung Cancer; 2013 Nov; 14(6):658-65. PubMed ID: 23867391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
    Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
    Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
    Shi L; Xi J; Xu X; Peng B; Zhang B
    Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis.
    Huang HL; Liu YM; Sung TY; Huang TC; Cheng YW; Liou JP; Pan SL
    Theranostics; 2019; 9(22):6676-6689. PubMed ID: 31588243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
    Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
    Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
    Igarashi H; Taniguchi H; Nosho K; Ishigami K; Koide H; Mitsuhashi K; Okita K; Takemasa I; Imai K; Nakase H
    Clin Transl Oncol; 2020 Jul; 22(7):1126-1137. PubMed ID: 31741141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer.
    Wang W; Wang H; Xiang L; Ni T; Jin F; Deng J; Zhang Y; Shintaro I; Zhou Y; Liu Y
    Oncol Rep; 2020 Jul; 44(1):77-90. PubMed ID: 32627002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer.
    Wang H; Huang R; Guo W; Qin X; Yang Z; Yuan Z; Wei Y; Mo C; Zeng Z; Luo J; Cai J; Wang H
    Clin Sci (Lond); 2020 Jul; 134(14):1973-1990. PubMed ID: 32677671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.